Delivery Order SPE2DB24D3013-SPE2DB25FFPSS
- Not listed
- The Defense Logistics Agency awarded a $17,412.86 delivery order to AmerisourceBergen Drug Corp for 180 tablets of Mesalamine 800 mg delayed-release medication, with an ultimate completion date of July 29, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly...
- The Defense Logistics Agency awarded a delivery order valued at $16,681.52 to AmerisourceBergen Drug Corp for the supply of Mesalamine 800 mg delayed-release tablets (180-count units). This firm fixed-price delivery order, issued on August 1, 2025, represents a non-set-aside competitive award with an ultimate completion date of August 4, 2025. The work will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, where the company serves as a major pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Mesalamine DR 1.2 GM tablets (120-count) with a ceiling value of $1,512.73. This firm fixed-price delivery order, which is non-set-aside and competitively awarded, will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 6, 2025. The delivery order falls under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $3,334.85 to AmerisourceBergen Drug Corp for the supply of Mesalamine DR 1.2 GM tablets (120-count units) on July 23, 2025, with an ultimate completion date of July 24, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Mesalamine DR 1.2 GM tablets (120-count units) under a firm fixed-price contract valued at $1,076.10. This non-set-aside award is part of a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $1 billion vehicle running through December 2026 that serves as the primary global pharmaceutical support mechanism for...
- The Defense Logistics Agency (DLA) awarded a $1,694.97 delivery order to AmerisourceBergen Drug Corp for the supply of Mesalamine DR 1.2 GM tablets (120-count unit) on August 15, 2025, with an ultimate completion date of August 18, 2025. This competitively awarded, firm fixed-price contract was issued without a set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under...
- The Defense Logistics Agency awarded a delivery order valued at $1,489.23 to AmerisourceBergen Drug Corp for the supply of Mesalamine DR 1.2 GM tablets (120 count) under a firm fixed price arrangement. The contract, which was competitively awarded with no set-aside designation, is scheduled for completion by August 5, 2025, with performance taking place at the contractor's facility in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $1,286.99 to AmerisourceBergen Drug Corp for 120 tablets of Mesalamine DR 1.2 GM on August 15, 2025, with completion targeted for August 18, 2025. This firm fixed price delivery order represents a non-set-aside award issued under competitive procurement procedures. The product will be delivered to the contractor's corporate office location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its headquarters as a major...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,739.99 to AmerisourceBergen Drug Corp for the supply of Mesalamine DR 1.2 GM tablets (120-count package) on August 5, 2025, with completion targeted for August 6, 2025. This contract utilizes firm fixed-price pricing with no set-aside designation, indicating competitive procurement. The award represents a child delivery order under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,793.28 to AmerisourceBergen Drug Corp for the supply of Mesalamine DR 1.2 GM tablets (120-count) with an ultimate completion date of August 19, 2025. This firm fixed-price delivery order, awarded without set-aside designation on August 18, 2025, will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider,...
- SPE2DB24D3013Indefinite Delivery Contract
- SPE2DB24D3013-SPE2DB25FFPSSDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $5,911.09 to AmerisourceBergen Drug Corp for the supply of Mesalamine 800 mg delayed-release tablets (180-count units) with an ultimate completion date of August 25, 2025. This is a firm fixed-price, non-set-aside contract awarded competitively on August 22, 2025, with performance at AmerisourceBergen's Conshohocken, Pennsylvania facility. The delivery order is issued under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare systems. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, is a critical vendor for federal medical procurement serving the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company's extensive contract portfolio with DLA demonstrates proven capability in supplying a broad range of pharmaceutical products and medical commodities across multiple therapeutic domains through competitive award mechanisms. This particular delivery order for Mesalamine, a gastrointestinal medication, exemplifies the routine pharmaceutical supplies distributed through the SPE2DX vehicle to support military medical operations globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.9k | 8/22/25 |